Robert A. Langish

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

37

H-Index

1

About

Dr. Robert A. Langish is a distinguished pharmaceutical scientist whose work has significantly advanced the field of drug metabolism and pharmacokinetics (DMPK). His primary research focuses on developing high-throughput analytical methodologies to accelerate drug discovery, particularly through liquid chromatography–mass spectrometry (LC-MS) technologies. Dr. Langish’s most notable contribution is the development of the MetFast assay, an automated high-throughput LC-MS process for assessing the metabolic stability of drug candidates. This groundbreaking work, published in 2007 and cited 37 times, provides a rapid, reliable method to evaluate microsomal cytochrome P450-mediated first-pass metabolism, enabling pharmaceutical researchers to identify promising compounds earlier in the discovery pipeline. By streamlining the assessment of metabolic stability—a critical determinant of a drug’s bioavailability and efficacy—Dr. Langish’s innovation has helped reduce attrition rates in drug development and accelerate the progression of candidate molecules toward clinical trials. His contributions exemplify the integration of automation and analytical chemistry in modern pharmaceutical profiling, making him a key figure in optimizing early-stage drug discovery processes for the industry.

Research Focus

Key Achievements

1
H-Index
1
Papers
37
Total Citations
37
Avg Citations/Paper
🏆 Most Cited Paper
An Automated High Throughput Liquid Chromatography–Mass Spectrometry Process to Assess the Metabolic Stability of Drug Candidates
37 citations · 2007
📈 Most Prolific Year: 2007 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago